Emerging evidence describes the glutaminolysis process promoted by KRAS-mutant CRC generating critical metabolites and epigenetic deregulation to support cancer cell proliferation, stemness and chemotherapy resistance [162]. The gene discussed is KRAS; the disease is colorectal carcinoma.